Evotec inks li­cense agree­ment with J&J; On­colyt­ic virus biotech prices $15M IPO

Drug dis­cov­ery and de­vel­op­ment play­er Evotec en­tered an­oth­er li­cens­ing deal with Big Phar­ma — this time with J&J’s Janssen.

The com­pa­nies put out word that they en­tered in­to a strate­gic col­lab­o­ra­tion and li­cense agree­ment with each oth­er that fo­cus­es on tar­get­ed im­mune-based can­cer ther­a­pies, to be com­mer­cial­ized by Janssen.

Ac­cord­ing to a state­ment, the col­lab­o­ra­tion will hinge on Evotec’s in­te­grat­ed drug dis­cov­ery and man­u­fac­tur­ing ca­pa­bil­i­ties. Dur­ing the pre-clin­i­cal R&D phase, the com­pa­nies will col­lab­o­rate close­ly — and then Janssen will take on full re­spon­si­bil­i­ty for both clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.